Asset Details
Do you wish to reserve the book?
Yttrium-90 Radiotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Preliminary Assessment of This Novel Treatment Option
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Yttrium-90 Radiotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Preliminary Assessment of This Novel Treatment Option
Do you wish to request the book?
Yttrium-90 Radiotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Preliminary Assessment of This Novel Treatment Option
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Yttrium-90 Radiotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Preliminary Assessment of This Novel Treatment Option
2010
Overview
Background
There are no treatment options for unresectable intrahepatic cholangiocarcinoma (ICC) with proven efficacy. The objective of this study was to present data on the safety and efficacy of a novel treatment option, yttrium-90 (
90
Y) radioembolization for unresectable ICC.
Methods
Twenty-five patients underwent resin-based
90
Y radioembolization for unresectable ICC between January 2004 and May 2009. Patients were assessed at 1 month and then at 3-month intervals after treatment. Radiologic response was evaluated with the Response Criteria in Solid Tumors (RECIST) criteria. Clinical and biochemical toxicities were prospectively recorded. Survival was calculated by the Kaplan-Meier method and potential prognostic variables were identified.
Results
No patient was lost to follow-up. The median follow-up was 8.1 (range, 0.4–56) months and the median survival after
90
Y radioembolization was 9.3 months. Two patients died within 1 month of treatment; the median follow-up for the remaining 23 was 8.9 (range, 1.5–56) months. Two factors were associated with an improved survival: peripheral tumor type (vs. infiltrative,
P
= .004) and Eastern Cooperative Oncology Group performance status of 0 (vs. 1 and 2,
P
< .001). On imaging follow-up of 23 patients, a partial response to treatment was observed in 6 patients (24%), stable disease in 11 patients (48%), and progressive disease in 5 patients (20%). The most common clinical toxicities were fatigue (64%) and self-limiting abdominal pain (40%). Two patients (8%) each developed grade III bilirubin and albumin toxicity. One patient (4%) developed grade III alkaline phosphatase toxicity.
Conclusions
90
Y radioembolization may be a relatively safe and efficacious treatment for unresectable ICC. In the absence of other effective therapeutic options, this treatment warrants further investigation.
Publisher
Springer-Verlag,Springer Nature B.V
Subject
Bile Duct Neoplasms - pathology
/ Bile Duct Neoplasms - radiotherapy
/ Bile Duct Neoplasms - surgery
/ Bile Ducts, Intrahepatic - radiation effects
/ Cholangiocarcinoma - pathology
/ Cholangiocarcinoma - radiotherapy
/ Cholangiocarcinoma - surgery
/ Female
/ Humans
/ Male
/ Medicine
/ Oncology
/ Surgery
